我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Immunotoxicity Assessment in Biopharmaceuticals Novel Strategies

Shahryar Kodama

Immunotoxicity assessment in the realm of biopharmaceuticals is a critical endeavor, given their intricate mechanisms of action and potential to elicit unique immune responses. Traditional methods for evaluating immunotoxicity may not adequately capture the complexities associated with these innovative therapies. This article explores novel strategies that are emerging to address the challenges of immunotoxicity assessment in biopharmaceuticals. From in silico models to high-throughput screening, organ-on-a-chip systems, and biomarker identification, these approaches promise to enhance our understanding of immune reactions to biopharmaceuticals and contribute to safer drug development. Regulatory considerations play a pivotal role in the adoption of these strategies, ensuring their integration into the evolving landscape of biopharmaceutical evaluation.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。